Chronic myelogenous leukaemia with p185(BCR/ABL) expression: Characteristics and clinical significance

Farhad Ravandi, Jorge Cortes, Maher Albitar, Ralph Arlinghaus, Jie Qiang Guo, Moshe Talpaz, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

We investigated the significance of p185(BCR/ABL) expression in patients with chronic myelogenous leukaemia (CML) in relation to disease features, therapy and outcome. Results of Western blot analysis for 1384 patients referred with a diagnosis of CML to our institution from 1989 to 1997 were reviewed. Clinical characteristics, results of cytogenetic analysis and RT- PCR for BCR rearrangement were analysed. Five patients with Ph-positive CML expressing the p185(BCR/ABL) hybrid protein were identified. By RT-PCR, bone marrow specimens of these patients were confirmed to have an ela2 junction. The median age at diagnosis of these patients was 55 years (range 43-76). All had elevated white cell counts at diagnosis (median 50 x 109/l, range 11.7- 163 x 109/l). Four patients had monocytosis (range 10-16%) with a low neutrophil/monocyte ratio in the peripheral blood (range 3.4-5.7). Patients presented with various stages of the disease (two in chronic-phase CP, two in accelerated-phase AP, and one in blastic-phase BP). The clinical course and therapy of the patients varied, with one patient receiving hydroxyurea only, three patients receiving hydroxyurea followed by interferon-α based regimens and bone marrow transplantation. The patient presenting in BP was treated with combination chemotherapy. The clinical outcome of the patients was also varied with one patient alive and in complete remission (with complete cytogenetic remission after transplant) and four patients dead after progression to more advanced stages. We conclude that patients with Ph- positive p185(BCR/ABL) CML frequently present with monocytosis and a low neutrophil/monocyte ratio in the peripheral blood, aiding the speculation that the presence of the p185(BCR/ABL) hybrid protein may contribute to a phenotype intermediate between CML and CMML. Of interest, the only other specific clinical feature identified was the absence of splenomegaly in four of five patients. There was no definite association with transformation to lymphoid blast phase.

Original languageEnglish (US)
Pages (from-to)581-586
Number of pages6
JournalBritish Journal of Haematology
Volume107
Issue number3
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hydroxyurea
Monocytes
Neutrophils
Blast Crisis
Polymerase Chain Reaction
Cytogenetic Analysis
Splenomegaly
Combination Drug Therapy
Bone Marrow Transplantation
Cytogenetics
Interferons

Keywords

  • CML
  • Monocytosis
  • P185(BCR/ABL)
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic myelogenous leukaemia with p185(BCR/ABL) expression : Characteristics and clinical significance. / Ravandi, Farhad; Cortes, Jorge; Albitar, Maher; Arlinghaus, Ralph; Guo, Jie Qiang; Talpaz, Moshe; Kantarjian, Hagop M.

In: British Journal of Haematology, Vol. 107, No. 3, 01.01.1999, p. 581-586.

Research output: Contribution to journalArticle

Ravandi, Farhad ; Cortes, Jorge ; Albitar, Maher ; Arlinghaus, Ralph ; Guo, Jie Qiang ; Talpaz, Moshe ; Kantarjian, Hagop M. / Chronic myelogenous leukaemia with p185(BCR/ABL) expression : Characteristics and clinical significance. In: British Journal of Haematology. 1999 ; Vol. 107, No. 3. pp. 581-586.
@article{9594248853c54ed391326fb8e0778c70,
title = "Chronic myelogenous leukaemia with p185(BCR/ABL) expression: Characteristics and clinical significance",
abstract = "We investigated the significance of p185(BCR/ABL) expression in patients with chronic myelogenous leukaemia (CML) in relation to disease features, therapy and outcome. Results of Western blot analysis for 1384 patients referred with a diagnosis of CML to our institution from 1989 to 1997 were reviewed. Clinical characteristics, results of cytogenetic analysis and RT- PCR for BCR rearrangement were analysed. Five patients with Ph-positive CML expressing the p185(BCR/ABL) hybrid protein were identified. By RT-PCR, bone marrow specimens of these patients were confirmed to have an ela2 junction. The median age at diagnosis of these patients was 55 years (range 43-76). All had elevated white cell counts at diagnosis (median 50 x 109/l, range 11.7- 163 x 109/l). Four patients had monocytosis (range 10-16{\%}) with a low neutrophil/monocyte ratio in the peripheral blood (range 3.4-5.7). Patients presented with various stages of the disease (two in chronic-phase CP, two in accelerated-phase AP, and one in blastic-phase BP). The clinical course and therapy of the patients varied, with one patient receiving hydroxyurea only, three patients receiving hydroxyurea followed by interferon-α based regimens and bone marrow transplantation. The patient presenting in BP was treated with combination chemotherapy. The clinical outcome of the patients was also varied with one patient alive and in complete remission (with complete cytogenetic remission after transplant) and four patients dead after progression to more advanced stages. We conclude that patients with Ph- positive p185(BCR/ABL) CML frequently present with monocytosis and a low neutrophil/monocyte ratio in the peripheral blood, aiding the speculation that the presence of the p185(BCR/ABL) hybrid protein may contribute to a phenotype intermediate between CML and CMML. Of interest, the only other specific clinical feature identified was the absence of splenomegaly in four of five patients. There was no definite association with transformation to lymphoid blast phase.",
keywords = "CML, Monocytosis, P185(BCR/ABL), Philadelphia chromosome",
author = "Farhad Ravandi and Jorge Cortes and Maher Albitar and Ralph Arlinghaus and Guo, {Jie Qiang} and Moshe Talpaz and Kantarjian, {Hagop M.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1046/j.1365-2141.1999.01736.x",
language = "English (US)",
volume = "107",
pages = "581--586",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Chronic myelogenous leukaemia with p185(BCR/ABL) expression

T2 - Characteristics and clinical significance

AU - Ravandi, Farhad

AU - Cortes, Jorge

AU - Albitar, Maher

AU - Arlinghaus, Ralph

AU - Guo, Jie Qiang

AU - Talpaz, Moshe

AU - Kantarjian, Hagop M.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - We investigated the significance of p185(BCR/ABL) expression in patients with chronic myelogenous leukaemia (CML) in relation to disease features, therapy and outcome. Results of Western blot analysis for 1384 patients referred with a diagnosis of CML to our institution from 1989 to 1997 were reviewed. Clinical characteristics, results of cytogenetic analysis and RT- PCR for BCR rearrangement were analysed. Five patients with Ph-positive CML expressing the p185(BCR/ABL) hybrid protein were identified. By RT-PCR, bone marrow specimens of these patients were confirmed to have an ela2 junction. The median age at diagnosis of these patients was 55 years (range 43-76). All had elevated white cell counts at diagnosis (median 50 x 109/l, range 11.7- 163 x 109/l). Four patients had monocytosis (range 10-16%) with a low neutrophil/monocyte ratio in the peripheral blood (range 3.4-5.7). Patients presented with various stages of the disease (two in chronic-phase CP, two in accelerated-phase AP, and one in blastic-phase BP). The clinical course and therapy of the patients varied, with one patient receiving hydroxyurea only, three patients receiving hydroxyurea followed by interferon-α based regimens and bone marrow transplantation. The patient presenting in BP was treated with combination chemotherapy. The clinical outcome of the patients was also varied with one patient alive and in complete remission (with complete cytogenetic remission after transplant) and four patients dead after progression to more advanced stages. We conclude that patients with Ph- positive p185(BCR/ABL) CML frequently present with monocytosis and a low neutrophil/monocyte ratio in the peripheral blood, aiding the speculation that the presence of the p185(BCR/ABL) hybrid protein may contribute to a phenotype intermediate between CML and CMML. Of interest, the only other specific clinical feature identified was the absence of splenomegaly in four of five patients. There was no definite association with transformation to lymphoid blast phase.

AB - We investigated the significance of p185(BCR/ABL) expression in patients with chronic myelogenous leukaemia (CML) in relation to disease features, therapy and outcome. Results of Western blot analysis for 1384 patients referred with a diagnosis of CML to our institution from 1989 to 1997 were reviewed. Clinical characteristics, results of cytogenetic analysis and RT- PCR for BCR rearrangement were analysed. Five patients with Ph-positive CML expressing the p185(BCR/ABL) hybrid protein were identified. By RT-PCR, bone marrow specimens of these patients were confirmed to have an ela2 junction. The median age at diagnosis of these patients was 55 years (range 43-76). All had elevated white cell counts at diagnosis (median 50 x 109/l, range 11.7- 163 x 109/l). Four patients had monocytosis (range 10-16%) with a low neutrophil/monocyte ratio in the peripheral blood (range 3.4-5.7). Patients presented with various stages of the disease (two in chronic-phase CP, two in accelerated-phase AP, and one in blastic-phase BP). The clinical course and therapy of the patients varied, with one patient receiving hydroxyurea only, three patients receiving hydroxyurea followed by interferon-α based regimens and bone marrow transplantation. The patient presenting in BP was treated with combination chemotherapy. The clinical outcome of the patients was also varied with one patient alive and in complete remission (with complete cytogenetic remission after transplant) and four patients dead after progression to more advanced stages. We conclude that patients with Ph- positive p185(BCR/ABL) CML frequently present with monocytosis and a low neutrophil/monocyte ratio in the peripheral blood, aiding the speculation that the presence of the p185(BCR/ABL) hybrid protein may contribute to a phenotype intermediate between CML and CMML. Of interest, the only other specific clinical feature identified was the absence of splenomegaly in four of five patients. There was no definite association with transformation to lymphoid blast phase.

KW - CML

KW - Monocytosis

KW - P185(BCR/ABL)

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=0032705902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032705902&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1999.01736.x

DO - 10.1046/j.1365-2141.1999.01736.x

M3 - Article

C2 - 10583263

AN - SCOPUS:0032705902

VL - 107

SP - 581

EP - 586

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -